Hopkins Lupus Cohort: 1999 Update

Rheumatic Disease Clinics of North America

Volumn 26, Issue 2, 2000, Pages 199-213

  Petri, Michelle ^b  

^a Hopkins Lupus Cohort   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTHRALGIA; ARTHRITIS; ATHEROSCLEROSIS; DISEASE ACTIVITY; ENVIRONMENTAL FACTOR; HEALTH STATUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MYOSITIS; ONSET AGE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0034087160     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70135-6     Document Type: Article

References (41)

1. S. Akkasilpa M. Minor D. Goldman Association of coping responses with fibromyalgia tender points in systemic lupus erythematosus patients [abstract] Arthritis Rheum 40 suppl 1997 S209
2. Austin H.A. III D.T. Boumpas E.M. Vaughan High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients Nephrol Dial Transplant 10 1995 1620 1628
3. M.A. Dooley S. Hogan C. Jennette Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network Kidney Int 51 1997 1188 1195
4. J.M. Esdaile M. Abrahamowicz L. Joseph Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail Arthritis Rheum 39 1996 370 378
5. W.J. Fessel Systemic lupus erythematosus in the community: Incidence, prevalence, outcome, and first symptoms; The high prevalence in black women Arch Intern Med 134 1974 1027 1035
6. D. Gladman E. Ginzler C. Goldsmith The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage Index for systemic lupus erythematosus Arthritis Rheum 39 1996 363 369
7. L. Gorgos D. Goldman M. Petri The ACR/SLICC Damage Index in systemic lupus erythematosus (SLE) [abstract] Arthritis Rheum 36 1993 A17
8. S. Manzi J.E. Riarie B. Carpenter Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity Arthritis Rheum 39 1996 1178 1188
9. M. Petri Age at onset of SLE affects disease manifestations and course [abstract] Arthritis Rheum 41 suppl 1998 S332
10. M. Petri The effect of education on the clinical manifestations and morbidity of systemic lupus erythematosus [abstract] Arthritis Rheum 40 suppl 1997 S118
11. M. Petri The effect of race on the presentation and course of SLE in the United States [abstract] Arthritis Rheum 40 suppl 1997 S162
12. M. Petri Male lupus differs from female lupus in presentation and outcome [abstract] Arthritis Rheum 40 suppl 1997 S162
13. M. Petri Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: An update Arthritis Care and Research 8 1995 137 145
14. M. Petri Raynaud's phenomenon is strongly associated with cutaneous, musculoskeletal and neuropsychiatric lupus [abstract] Arthritis Rheum 41 suppl 1998 S106
15. M. Petri Smoking is a risk factor for musculoskeletal, pulmonary and cardiac disease in systemic lupus erythematosus [abstract] Arthritis Rheum 40 suppl 1997 S118
16. M. Petri Thrombosis and systemic lupus erythematosus: The Hopkins Lupus Cohort perspective Scand J Rheumatol 25 1996 191 193
17. M. Petri J. Allbritton Antibiotic allergy in SLE: A case-control study J Rheumatol 19 1992 265 269
18. M. Petri C. Civelek Discordance of myocardial SPECT and carotid duplex in systemic lupus erythematosus (SLE) [abstract] Arthritis Rheum 41 suppl 1998 S218
19. M. Petri U. Hamper Frequency of atherosclerosis detected by carotid duplex in SLE [abstract] Arthritis Rheum 40 suppl 1997 S219
20. M. Petri J. Allbritton Hair product use in systemic lupus erythematosus: A case-control study Arthritis Rheum 35 1992 625 629
21. M. Petri M. Minor L. Magder Fibromyalgia (FM) and disease activity in systemic lupus erythematosus: Role of race and socioeconomic status Am J Med 91 1991 345 353
22. M. Petri D. Spence L.R. Bone Coronary artery disease risk factors in the Hopkins Lupus Cohort: Prevalence, patient recognition, and preventive practices Medicine 71 1992 291 302
23. M. Petri M. Genovese E. Engle Definition, incidence and clinical description of flare in systemic lupus erythematosus: A prospective cohort study Arthritis Rheum 34 1991 937 944
24. M. Petri C. Lakatta L. Magder Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis Am J Med 96 1994 254 259
25. M. Petri M. Conroy E. Caffentzis The evolution of systemic lupus erythematosus (SLE) [abstract] Arthritis Rheum 36 suppl 1993 S274
26. M. Petri M. Rheinschmidt Q. Whiting-O'Keefe The frequency of lupus anticoagulant in systemic lupus erythematosus: A study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody Ann Intern Med 106 1987 524 531
27. M. Petri S.G. Barr A. Zonana-Nach Measures of disease activity, damage, and health status: The Hopkins Lupus Cohort experience J Rheumatol 26 1999 502 503
28. M. Petri S. Perez-Gutthann J.C. Longenecker Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status Am J Med 91 1991 345 353
29. M. Petri R. Roubenoff G.E. Dallal Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus Lancet 348 1996 1120 1124
30. M. Petri S. Perez-Gutthann D. Spence Risk factors for coronary artery disease in patients with systemic lupus erythematosus Am J Med 93 1992 513 519
31. P. Rahman D.D. Gladman M.B. Urowitz Efficacy of antimalarial therapy in cutaneous lupus in smokers versus nonsmokers [abstract] Arthritis Rheum 40 suppl 1997 S58
32. M.W. Ropes Systemic Lupus Erythematosus 1976 Harvard University Press Cambridge 173
33. A.J.G. Swaak E.J. Nieuwenhuys R.J.T. Smeenk Changes in clinical features of patients with systemic lupus erythematosus followed prospectively over 2 decades Rheumatol Int 12 1992 71 75
34. ter Borg E.J. G. Horst E.J. Hummel Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: A long-term, prospective study Arthritis Rheum 33 1990 634 643
35. E. Tsakonas L. Joseph J.M. Esdaile A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group Lupus 7 1998 80 85
36. K.M. Uramoto C.J.J. Michet J. Thumboo Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992 Arthritis Rheum 42 1999 46 50
37. M.B. Urowitz A.A.M. Bookman B.E. Koehler The bimodal mortality pattern of systemic lupus erythematosus Am J Med 60 1976 221 225
38. M.M. Ward S. Studenski Clinical prognostic factors in lupus nephritis: The importance of hypertension and smoking Arch Intern Med 152 1992 2082 2088
39. Ware J.E. Jr C.D. Sherbourne The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection Med Care 30 1992 473 483
40. F. Wolfe H.A. Smythe M.B. Yunus The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicentre Criteria Committee Arthritis Rheum 33 1990 160 172
41. A. Zonana-Nacach L. Magder S. Barr Damage in SLE and its association with prednisone [abstract] Arthritis Rheum 41 suppl 1998 S218